Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthLucet TMS Coverage Policy Update 2026 | OpenPayer
    Ask Trek AI about this page
    ModifiedlucetPolicy 00121

    Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders

    Customize your policy alerts

    Sign up for lucet Policy 00121 alerts

    Get alerted when Policy 00121 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of transcranial magnetic stimulation using an FDA-cleared device for major depressive disorder and identifies TMS uses that are investigational. It applies to products administered or underwritten by Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc., subject to the member’s contract.

    Policy Summary
    Payerlucet
    PolicyTranscranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders
    Policy CodePolicy 00121
    Change TypeModified
    Effective DateMar 1, 2026
    Last ReviewDec 4, 2025
    Next Review DateDec 1, 202612d
    Key ActionBefore TMS, document failure of an adequate psychotherapy trial and one qualifying medication or alternative-treatment pathway.
    SourceLink
    POLICY UPDATE CHANGES

    The eligible-for-coverage statement for TMS for treatment-resistant depression was revised to require use of an FDA-cleared device and modality.

    The policy history records multiple format revisions, including addition of FDA and other governmental regulatory approval information, with some entries explicitly stating that there was no substance change to the policy.

    Coverage changed from investigational to eligible with criteria for transcranial magnetic stimulation of the brain for treatment-resistant depression.

    The policy history identifies continued transcranial magnetic stimulation as maintenance therapy and treatment of other psychiatric or neurologic disorders as investigational.

    Information on TMS modalities, including theta burst stimulation, was added to the Policy Guidelines.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    15+Minimum age for potentially eligible TMS
    2Required antidepressant trials
    6 weeksMinimum adequate antidepressant trial
    ≥80%Required antidepressant-trial adherence
    30 sessionsTypical maximum conventional TMS course
    TRDCovered indication

    Coverage Criteria

    Initial Therapy for Major Depressive Disorder

    Coverage for TMS of the brain may be considered when benefits are available under the member's contract, medical-necessity criteria are met, and ALL of the following requirements are satisfied.

    ALL of the following

    • Individual is age 15 or older.
    • Treatment is for a confirmed diagnosis of severe major depressive disorder, single or recurrent, documented by standardized rating scales that reliably measure depressive symptoms.
    • ONE of the following

      • Inadequate response to antidepressants

        • Individual has tried and had an inadequate response to 2 antidepressant agents from 2 different antidepressant classes, including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, bupropion, or mirtazapine.
        • Adequate trial requirements

          • Each trial lasted at least 6 weeks at generally accepted doses, or was of sufficient duration at generally accepted doses as determined by the treating physician.
          • Individual was at least 80% adherent to the agent during the trial.
      • Individual is unable to tolerate a therapeutic medication dose because of distinct side effects.
      • Individual has a history of response to TMS in a previous depressive episode, with at least 3 months since the prior episode and at least 50% improvement in symptoms documented by a standardized rating scale.
      • Electroconvulsive therapy (ECT) candidate

        • Individual is a candidate for ECT.
        • ECT would not be clinically superior to TMS.
    • Individual has failed a trial of psychotherapy known to be effective for major depressive disorder, delivered with adequate frequency and duration, without significant improvement in depressive symptoms documented by standardized rating scales.

    Investigational and Not Covered

    Coverage is not available for investigational medical treatments or procedures, drugs, devices, or biological products, including services provided under the investigational arm of a clinical trial or clinical study.

    Investigational and not covered

    • TMS for major depressive disorder when the patient-selection criteria are not met.
    • Continued TMS of the brain as maintenance therapy or booster treatment.
    • Subsequent TMS treatment after a prior episode of repetitive TMS or deep TMS failed to achieve at least a 50% reduction in depression severity scores on a standardized rating scale by the end of acute-phase treatment.
    • Novel delivery mechanisms, including multiple TMS sessions per day.
    • TMS for other psychiatric or neurologic disorders, including bipolar disorder, schizophrenia, obsessive-compulsive disorder, or migraine headaches.

    Treatment-Resistant Depression — Criteria for Consideration

    TMS may be considered for treatment-resistant depression (TRD) when the evidence supports an improvement in the net health outcome and the applicable coverage criteria are met.

    TRD consideration

    • Individual has treatment-resistant major depressive disorder and meets the applicable patient-selection criteria for TMS.
    • TMS is delivered as an acute treatment course using an FDA-cleared device and modality.
    • The treatment plan addresses the absence of reasonable alternatives aside from ECT and weighs the potential short-term benefits and harms of TMS compared with ECT.

    Treatment-Resistant Depression Versus Investigational Uses

    Coverage is limited to eligible TMS treatment of major depressive disorder and does not extend to investigational uses.

    Covered category

    • TMS for treatment-resistant major depressive disorder in individuals age 15 or older when all patient-selection criteria are met and an FDA-cleared device and modality is used.
    • Investigational or excluded category

      • TMS for major depressive disorder when patient-selection criteria are not met.
      • Maintenance or booster TMS after the acute treatment course.
      • Subsequent treatment after inadequate response to a prior repetitive TMS or deep TMS course, defined as failure to achieve at least a 50% reduction in depression severity by the end of acute treatment.

    FDA-Cleared Device and Modality Coverage Statement

    For treatment-resistant depression, eligible TMS coverage requires use of an FDA-cleared device and modality. Covered modalities can include, but are not limited to, conventional TMS, deep TMS, and theta burst stimulation.

    ALL of the following

    • TMS is used to treat treatment-resistant depression.
    • The device and modality used are FDA-cleared for the applicable treatment.

    FDA-Cleared Device and Modality Requirement

    The covered TMS service must be administered with an FDA-cleared device and modality; the coverage statement includes conventional TMS, deep TMS, and theta burst stimulation.

    ALL of the following

    • Treatment is delivered using an FDA-cleared TMS device.
    • Treatment is delivered using an FDA-cleared modality, which may include conventional TMS, deep TMS, or theta burst stimulation.

    Coverage is available only for eligible services when benefits are available under the member's contract and applicable medical-necessity criteria are met. TMS uses that do not meet the stated patient-selection criteria, maintenance or booster treatment, novel delivery mechanisms, and treatment of other psychiatric or neurologic disorders are investigational and not covered.

    TMS should not be used when ECT would be clinically superior, including cases involving psychosis, acute suicidal risk, catatonia, or life-threatening inanition. Contraindications to repetitive TMS include seizure disorder or a history of seizure with increased future risk; acute or chronic psychotic symptoms or disorders in the current depressive episode; neurologic conditions including epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, repetitive or severe head trauma, or central nervous system tumors; excessive alcohol or illicit-substance use within the last 30 days that may increase seizure risk; and an implanted magnetic-sensitive device within 30 centimeters or less of the TMS coil or other implanted metal, including cochlear implants, implanted cardioverter-defibrillators, pacemakers, vagus nerve stimulators, aneurysm clips or coils, staples, or stents.

    Continued TMS of the brain as maintenance therapy or booster treatment is investigational and not covered. TMS for psychiatric or neurologic disorders other than major depressive disorder, including bipolar disorder, schizophrenia, obsessive-compulsive disorder, and migraine headaches, is also investigational.

    Historical policy statements identifying maintenance therapy and other psychiatric or neurologic disorders as investigational do not expand current coverage. Maintenance or booster treatment and TMS for non-major-depressive psychiatric or neurologic disorders remain excluded as investigational uses.

    Coding and Operational Parameters

    FDA Product Codesmixed
    GWFFDA product code for devices for transcranial stimulation used for diagnostic purposes
    OKPFDA product code for migraine headache pain devices
    OBPFDA product code for devices cleared for major depressive disorder
    QCIFDA product code for devices cleared for obsessive-compulsive disorder
    FDA Clearance Numbersmixed
    K231926NeuroStar Advanced Therapy System FDA clearance number
    K243869Magstim Horizon FDA clearance number
    K251125MagVenture stimulator FDA clearance number
    K193006MagVenture TMS Therapy System FDA clearance number
    K230735Ultimate rTMS for OCD (M-series) FDA clearance number
    K233742CloudTMS Edge for OCD FDA clearance number
    K230358Savi Dual Migraine Therapy FDA clearance number
    K222171Horizon 3.0 TMS Therapy System FDA clearance number
    K220625Stimulation Therapy System FDA clearance number
    K083538NeuroStar FDA clearance number
    1–10 of 19
    1/2
    PHQ-9 severe depression
    PHQ-9 score range0-27
    Severe depression threshold20-27
    Scale formatValidated, standardized 9-item depression rating scale
    Typical conventional TMS course
    FrequencyUsually no more than 5 days per week
    Duration6 weeks
    Total sessions30 sessions

    Provider Requirements and Denial Risks

    Prior Authorization

    Coverage Criteria Must Be Met

    Before requesting TMS, verify that the member's contract includes benefits for the service and that all applicable medical-necessity criteria are satisfied. Coverage may be considered for FDA-cleared TMS modalities, including conventional TMS, deep TMS, and theta burst stimulation, for major depressive disorder in individuals age 15 or older.

    • Benefits must be available under the member's contract or certificate.
    • All medical-necessity criteria and policy guidelines must be met.
    • Use an FDA-cleared device and modality for the requested treatment.
    Step Therapy

    Required Prior Treatment Pathways

    Document that the patient has failed an adequate psychotherapy trial and satisfies one permitted medication or alternative-treatment pathway before requesting TMS for major depressive disorder.

    • Psychotherapy must be of adequate frequency and duration, without significant improvement in depressive symptoms, with symptom change documented using a standardized rating scale.

    Background

    Transcranial magnetic stimulation (TMS) is a noninvasive cortical stimulation technique. A coil positioned over the scalp generates a magnetic field that passes through the scalp and skull to stimulate neuronal function. TMS modalities differ in stimulation intensity, frequency, pattern, and treatment site; examples described in the policy include conventional TMS, bilateral TMS, deep TMS, and theta-burst stimulation.

    Definitions

    PHQ-9
    PurposeAssesses depression severity
    Structure9 items based on DSM criteria for major depressive disorder
    Severe-depression range20-27
    Transcranial magnetic stimulation
    MethodNoninvasive delivery of electrical stimulation to the brain
    MechanismRapidly alternating current passes through a scalp coil and produces a magnetic field
    EffectThe magnetic field passes through the scalp and bone and stimulates neuronal function

    Treatment Modalities

    Transcranial Magnetic Stimulation (TMS): Modality and Core Treatment Criteria

    TMS may be considered when ALL core treatment and safety requirements are met.

    TMS for severe major depressive disorder

    • Safety and facility requirements: An attendant trained in basic cardiac life support, seizure management, and equipment use is present; adequate resuscitation equipment is available; and emergency services or a code team can respond within 5 minutes.Emergency response available within 5 minutes

    Transcranial Magnetic Stimulation (TMS): Evidence or Modality Criteria

    TMS may be considered for treatment-resistant depression when the policy’s criteria are met.

    Evidence-supported TMS indication: The individual has treatment-resistant depression and meets the policy’s specific criteria for TMS.

    Visit and Session Limits

    Conventional TMS acute treatment course
    Treatment typeConventional TMS acute treatment course
    Usual maximumNo more than 30 sessions
    Typical scheduleUsually no more than 5 days per week for 6 weeks
    IndividualizationThe treatment plan may be individualized based on device type, safety and side-effect considerations, and response to treatment
    Policy Summary
    Payerlucet
    PolicyTranscranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders
    Policy CodePolicy 00121
    Change TypeModified
    Effective DateMar 1, 2026
    Last ReviewDec 4, 2025
    Next Review DateDec 1, 202612d
    Key ActionBefore TMS, document failure of an adequate psychotherapy trial and one qualifying medication or alternative-treatment pathway.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Operational ParametersProvider Requirements and Denial RisksBackgroundDefinitionsTreatment ModalitiesVisit and Session Limits
    Novel delivery mechanisms, including multiple sessions per day.
  1. TMS for psychiatric or neurologic disorders other than major depressive disorder, including bipolar disorder, schizophrenia, obsessive-compulsive disorder, and migraine headaches.
  2. Emergency response availability
    Emergency responseEmergency services or a code team should be available within 5 minutes
    Facility responsibilityMaintain awareness of emergency-service response times
    Review frequencyEmergency-response relationships reviewed at least annually, including mock drills
    Implanted magnetic-sensitive device distance
    Restricted distance30 centimeters or less from the TMS magnetic coil
    Device concernImplanted magnetic-sensitive medical devices
    Other affected itemsImplanted metal items, including cochlear implants, pacemakers, defibrillators, vagus nerve stimulators, and aneurysm clips or coils
  3. In addition, document one of the following: inadequate response to two antidepressants from two different classes; inability to tolerate a therapeutic medication dose because of distinct side effects; response to TMS during a prior depressive episode; or candidacy for ECT when ECT would not be clinically superior.
  4. Unsupported block type: documentation2026-11-15

    Documentation Required

    Medication Trial Documentation

    For the antidepressant pathway, document inadequate response to two agents from two different antidepressant classes and show that each trial was adequate.

    • Eligible classes include SSRIs, SNRIs, tricyclic antidepressants, bupropion, and mirtazapine.
    • Each trial must last at least 6 weeks at generally accepted doses, or a sufficient duration determined by the treating physician at generally accepted doses.
    • Document adherence of at least 80% during each trial.
    Documentation Required

    Medication Intolerance Documentation

    If the medication pathway is based on intolerance, document that the patient could not tolerate a therapeutic medication dose because of distinct side effects.

    • Identify the medication, therapeutic dose, treatment dates, and duration.
    • Describe the distinct side effects and why they required discontinuation or prevented continuation at a therapeutic dose.
    Documentation Required

    Prior TMS Response Documentation

    If eligibility relies on prior TMS response, document the prior depressive episode, timing, treatment response, and standardized measurement supporting the response.

    • At least 3 months must have elapsed since the prior depressive episode.
    • Document at least 50% symptom improvement using a standardized rating scale.
    Documentation Required

    ECT Alternative Documentation

    When using the ECT alternative pathway, document that the patient is an ECT candidate and explain why ECT would not be clinically superior to TMS for the current episode.

    • Include the clinical rationale for selecting TMS instead of ECT.
    • Do not use TMS where ECT is clinically superior, including psychosis, acute suicidal risk, catatonia, or life-threatening inanition.
    Denial Risk

    Investigational Services Excluded

    Do not submit investigational TMS services for coverage. Services provided under the investigational arm of a clinical trial or clinical study are excluded from benefits.

    • Clinical-trial or clinical-study investigational-arm services are not covered.
    • Investigational treatment, procedures, drugs, devices, and biological products are excluded under the member's benefits.
    Denial Risk

    Selection Criteria Not Met

    Expect denial when TMS is requested for major depressive disorder without documentation that the policy's patient-selection criteria are met.

    • The request must support the severe major depressive disorder diagnosis, required prior treatment pathway, and all other applicable selection criteria.
    • TMS for major depressive disorder when selection criteria are not met is considered investigational.
    Denial Risk

    Maintenance or Booster Treatment

    Do not request continued TMS as maintenance therapy or booster treatment as covered acute treatment; the policy considers these uses investigational.

    • Maintenance therapy after the acute course is investigational.
    • Booster or continued treatment is investigational and not available for coverage under this policy.
    Denial Risk

    Subsequent or Accelerated Delivery After Nonresponse

    Subsequent TMS treatment is investigational when a prior acute repetitive TMS or deep TMS episode failed to produce the required response, or when a novel accelerated delivery mechanism is used.

    • Prior nonresponse means less than a 50% reduction in depression severity on a standardized rating scale by the end of acute-phase treatment.
    • Multiple TMS sessions per day and other novel delivery mechanisms are investigational.
    Denial Risk

    Other Psychiatric or Neurologic Indications

    TMS for psychiatric or neurologic conditions other than major depressive disorder is investigational under this policy.

    • Examples include bipolar disorder, schizophrenia, obsessive-compulsive disorder, and migraine headaches.
    • Other examples include generalized anxiety disorder, panic disorder, posttraumatic stress disorder, substance use disorder or craving, amyotrophic lateral sclerosis, chronic pain, epilepsy, fibromyalgia, Parkinson disease, and stroke recovery.
    Denial Risk

    Contraindications

    Screen for and document contraindications before repetitive TMS. Do not proceed when seizure risk, qualifying neurologic disease, active psychosis, recent substance use, or unsafe implanted hardware is present.

    • Seizure disorder or a history of seizure with increased future seizure risk.
    • Acute or chronic psychotic symptoms or disorders in the current depressive episode.
    • Epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, severe or repetitive head trauma, or central nervous system tumors.
    • Excessive alcohol or illicit-substance use within the preceding 30 days that may increase seizure risk.
    • Magnetic-sensitive implanted devices or other implanted metal within 30 cm or less of the TMS coil, including cochlear implants, pacemakers, defibrillators, vagus nerve stimulators, aneurysm clips or coils, staples, and stents.
    Denial Risk

    ECT Clinically Superior

    Document the clinical comparison of TMS and ECT. TMS should not be used when ECT is expected to provide a clinically superior option.

    • Consider ECT instead of TMS in cases involving psychosis, acute suicidal risk, catatonia, or life-threatening inanition.
    • If TMS is selected because the patient declines ECT or because the balance of benefits and harms favors TMS, document that rationale.
    Documentation Required

    Treatment Safety Documentation

    Ensure the treatment setting meets all required safety safeguards before administering repetitive TMS.

    • Use a U.S. Food and Drug Administration-cleared device and an appropriately selected patient age 15 or older.
    • Treatment must be delivered by health care professionals adequately trained and experienced in the specific techniques used.
    • Maintain a trained attendant at all times who is qualified in basic cardiac life support, seizure and complication management, and equipment operation.
    • Maintain adequate resuscitation equipment, including suction and oxygen.
    • Confirm emergency services or a code team can respond within 5 minutes; review these arrangements at least annually and conduct mock drills.
    Documentation Required

    Device, Personnel, and Facility Requirements

    Use only an FDA-cleared device and modality, and document the qualifications and training of the treating personnel and the facility's emergency preparedness.

    • The device and requested modality may include conventional TMS, deep TMS, or theta burst stimulation when FDA-cleared.
    • Document provider training and experience with the specific TMS technique.
    • Document the attendant, resuscitation equipment, emergency response time, annual review, and mock-drill requirements.
    Denial Risk

    Insufficient Evidence for Non-TRD Indications

    Do not represent TMS for migraine, OCD, or other non-TRD indications as established covered treatment. The evidence is insufficient to determine improvement in the net health outcome for these uses.

    • Migraine evidence is limited by substantial dropout and post hoc analysis, with no recent device studies identified.
    • OCD studies show variable parameters, limited durability, and a need for additional adequately powered trials.
    • Evidence for other disorders is generally based on small, low-quality, heterogeneous trials without established stimulation parameters or durable efficacy.
    Denial Risk

    Investigational Maintenance or Non-Depression Use

    The policy's historical and operative language excludes maintenance TMS and TMS for psychiatric or neurologic conditions other than the covered depression indication as investigational.

    • Historical policy updates repeatedly identify maintenance therapy and other psychiatric or neurologic disorders as investigational.
    • Do not rely on older policy wording to support coverage for these excluded uses.
    Denial Risk

    Investigational Indications

    Maintenance therapy and other psychiatric or neurologic indications remain investigational and should not be submitted as covered TMS under the current policy.

    • Maintenance treatment, booster treatment, and other non-depression psychiatric or neurologic uses are excluded from coverage as investigational.
    • Apply the current operative coverage criteria rather than historical policy-history fragments.
    Adequate antidepressant trial
    Minimum trial durationAt least 6 weeks
    DoseGenerally accepted doses
    Clinical sufficiencyA sufficient duration determined by the treating physician may apply
    AdherenceAt least 80% adherence during the trial
    Lack of response to prior TMS
    Assessment pointBy the end of acute-phase treatment
    StandardDepression severity measured on a standardized rating scale
    Response thresholdFailure to achieve at least a 50% reduction in depression severity
    Transcranial magnetic stimulation (TMS)
    MethodNoninvasive delivery of electrical stimulation to the brain
    EquipmentA coil positioned over the scalp
    MechanismRapidly alternating current produces a magnetic field that passes through the scalp and skull and stimulates neuronal function
    Treatment-resistant depression (TRD)
    MeaningDepression that has not adequately responded to prior treatment
    Policy contextDefinition used in the policy's evidence discussion
    Operational criteriaSpecific operational criteria are not provided in this policy window
    Deep TMS
    ModalityDeep transcranial magnetic stimulation
    EquipmentH-coil helmet
    Stimulation areaDesigned to encompass a broader surface area and stimulate deeper brain structures than conventional TMS
    Theta-burst stimulation
    ModalityTheta-burst stimulation
    IntensityLower intensities than conventional TMS
    IntervalsShorter intervals than conventional TMS
    NCT
    AbbreviationNCT
    MeaningNational clinical trial
    ExampleNCT05331937 identifies an ongoing clinical trial

    The evidence includes sham-controlled randomized trials and meta-analyses supporting conventional TMS and theta burst stimulation for selected individuals with treatment-resistant depression.

    TMS for Migraine, OCD, and Other Psychiatric or Neurologic Disorders

    These uses are investigational or not supported for coverage under the policy.

    Non-depression indications: TMS is requested for migraine, obsessive-compulsive disorder, or another psychiatric or neurologic disorder rather than major depressive disorder.

    The policy concludes that evidence is insufficient to demonstrate improvement in the net health outcome. Other examples include bipolar disorder, generalized anxiety disorder, panic disorder, PTSD, schizophrenia, substance use disorder and craving, ALS, chronic pain, epilepsy, fibromyalgia, Parkinson disease, and stroke recovery.

    Transcranial Magnetic Stimulation: Historical Eligibility Criteria

    Historical policy language identified the following eligibility category.

    Historical covered indication: TMS of the brain for treatment-resistant depression was changed from investigational to eligible for coverage with criteria.

    This historical entry does not contain the current detailed medical-necessity criteria.

    Transcranial Magnetic Stimulation: Historical Covered and Investigational Uses

    Historical policy language distinguishes the covered indication from investigational uses.

    Historical TMS indication

    • Covered category: Treatment-resistant depression
    • Investigational categories: Maintenance therapy and other psychiatric or neurologic disorders

    Transcranial Magnetic Stimulation: Historical Maintenance and Non-Depression Criteria

    The following uses are identified as investigational.

    Historical investigational TMS uses: Continued TMS as maintenance therapy and TMS treatment for psychiatric or neurologic disorders other than treatment-resistant depression are investigational.

    This is historical policy language; it does not add current detailed treatment criteria.

    Transcranial Magnetic Stimulation: FDA-Cleared Device and Modality Revision

    Historical coverage language required an FDA-cleared device and modality for treatment-resistant depression.

    FDA-cleared TMS modality: TMS for treatment-resistant depression is eligible for coverage when delivered using an FDA-cleared device and modality.

    The available history records a wording revision and does not reproduce the complete surrounding criterion.

    Transcranial Magnetic Stimulation: Named FDA-Cleared Modalities

    Eligible FDA-cleared modalities include, but are not limited to, the following examples.

    Named FDA-cleared TMS modalities: TMS for treatment-resistant depression must use an FDA-cleared device and modality.

    Examples identified in the policy are conventional TMS, deep TMS, and theta burst stimulation; the examples are not exhaustive.